Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Net Cash Flow (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Net Cash Flow for 3 consecutive years, with -$7.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow rose 13.61% to -$7.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$32.5 million, a 312.5% decrease, with the full-year FY2024 number at $12.6 million, up 192.9% from a year prior.
  • Net Cash Flow was -$7.0 million for Q3 2025 at Mereo BioPharma, up from -$7.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $38.9 million in Q2 2024 to a low of -$9.7 million in Q1 2023.
  • A 3-year average of -$2.2 million and a median of -$7.8 million in 2025 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 601.39% in 2024; the steepest drop was 176.79% in 2024.
  • Mereo BioPharma's Net Cash Flow stood at -$6.8 million in 2023, then crashed by 39.34% to -$9.5 million in 2024, then rose by 25.91% to -$7.0 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Net Cash Flow are -$7.0 million (Q3 2025), -$7.8 million (Q2 2025), and -$8.2 million (Q1 2025).